|
T6230 |
Imatinib
|
STI571,CGP057148B,ST-1571 |
SARS-CoV
,
Bcr-Abl
,
PDGFR
,
c-Kit
,
Autophagy
|
|
Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with oral activity. Imatinib has antitumor activity for the tre... |
|
T11641 |
N-Desmethyl imatinib
|
Imatinib metabolite N-Desmethyl imatinib,Norimatinib |
Bcr-Abl
,
PDGFR
,
c-Kit
,
Drug Metabolite
|
|
N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR. |
|
T1621 |
Imatinib Mesylate
|
ST-1571 Mesylate,STI-571,CGP-57148B |
Bcr-Abl
,
PDGFR
,
c-Kit
,
Autophagy
|
|
Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, respectively). |
|
T67847 |
Imatinib impurities3
|
|
Bcr-Abl
,
PDGFR
,
c-Kit
|
|
Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively. |
|
T40504 |
N-Desmethyl imatinib mesylate
|
ImatinibmetaboliteN-Desmethylimatinibmesylate,N-Desmethyl imatinib mesylate,Norimatinib mesylate |
|
|
Norimatinib mesylate, also known as N-Desmethyl imatinib mesylate, is a metabolite derived from Imatinib, which acts as a potent multi-target inhibitor of v-Abl, c-Kit, and PDGFR. |
|
T19451 |
N-Desmethyl imatinib-d8
|
Norimatinib D8,Imatinib metabolite N-Desmethyl imatinib D8,N-Desmethyl imatinib D8 |
Others
|
|
N-Desmethyl imatinib D8 is a deuterium labeled Imatinib metabolite N-Desmethyl Imatinib. |
|
T22859 |
Imatinib hydrochloride
|
|
Others
|
|
Imatinib is a multi-target inhibitor of v-Abl, c-Kit, and PDGFR (IC50: 0.6 μM, 0.1 μM, and 0.1 μM, respectively). Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), and... |
|
T19015 |
Imatinib Acid
|
|
Others
|
|
Imatinib Acid is usually used as a fluorescent probe or labeled chemical. |
|
T11639 |
Imatinib D4
|
CGP-57148B D4,STI571 D4 |
Others
|
|
Imatinib D4 is a deuterium-labeled Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, PDGFR, v-Abl, and c-kit kinase activity. |
|
T11640 |
Imatinib-d8
|
CGP-57148B D8,STI571 D8 |
Others
|
|
Imatinib D8 is a deuterium-labeled Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that inhibits BCR/ABL, PDGFR, v-Abl, and c-kit kinase activity. |
|
T18592 |
Imatinib carbaldehyde
|
CGP-57148B carbaldehyde,STI571 carbaldehyde,PROTAC ABL binding moiety 1 |
Others
|
|
Imatinib carbaldehyde (also known as CGP-57148B carbaldehyde) is a compound derived from Imatinib, an inhibitor of the ABL protein. Imatinib carbaldehyde binds to the IAP ligand with the assistance of a linker, resulting... |
|
T73973 |
Imatinib Impurity E
|
|
|
|
Imatinib Impurity E is a specific impurity found in Imatinib, an orally available inhibitor of multiple tyrosine kinases, including BCR/ABL, v-Abl, PDGFR, and c-kit. Imatinib (STI571) operates by semi-competitively inhib... |
|
T64338 |
AKI603
|
AKI 603,AKI-603 |
Aurora Kinase
|
|
AKI603 is a novel small molecule inhibitor of Aurora kinase A (AurA)(IC50 = 12.3 nM). AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in l... |
|
T3071 |
Olverembatinib
|
GZD 824 |
Bcr-Abl
|
|
Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM). |
|
T2429 |
Olverembatinib dimesylate
|
GZD824 Dimesylate,HQP1351 |
Bcr-Abl
|
|
Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I). |
|
T1448L |
Dasatinib monohydrate
|
BMS-354825 Monohydrate |
Apoptosis
,
Bcr-Abl
,
Src
,
c-Kit
,
Ephrin Receptor
,
Autophagy
|
|
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activit... |
|
T27555 |
HS-438
|
HS 438 |
|
|
HS-438 inhibits imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. |
|
T71144 |
Nilotinib N-oxide
|
|
|
|
Nilotinib N-oxide is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. |
|
T23617 |
Aclacinomycin
|
Aclacinomycins,Siwenmycin |
|
|
Aclacinomycin A is an anthracycline drug. It sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation. It is used in the treatment of cancer. |
|
T18694 |
SNIPER(ABL)-050
|
|
Others
|
|
SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker. This conjugation results in the reduction of BCR-ABL protein[1]. |
|
T24496 |
MPT0B002
|
MPT-0-B-002,MPT 0 B 002 |
|
|
MPT0B002 is a microtubule inhibitor that acts by downregulating T315I mutant Bcr-Abl and inducing apoptosis of imatinib-resistant chronic myeloid leukemia cells. |
|
T69045 |
ON012380
|
|
|
|
ON012380 is a non-ATP-competitive Bcr-Abl inhibitor, potently inhibiting imatinib-resistant Bcr-Abl mutants such as T315I. |
|
T68338 |
Nilotinib hydrochloride dihydrate
|
|
|
|
Nilotinib hydrochloride dihydrate is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. |
|
T71068 |
Nilotinib dihydrochloride dihydrate
|
|
|
|
Nilotinib dihydrochloride dihydrate is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. |
|
T61465 |
PPARγ agonist 3
|
|
|
|
PPARγ agonist 3, also known as Compound 18a, is a potent and selective agonist of PPARγ. This compound does not exhibit cytotoxicity towards both non-resistant and resistant cells. Notably, PPARγ agonist 3 demonstrates a... |
|
T68581 |
AP23464
|
|
|
|
AP23464 is a potent adenosine 5'-triphosphate (ATP)-based inhibitor of Src and Abl kinases, displays antiproliferative activity against a human CML cell line and Bcr-Abl-transduced Ba/F3 cells (IC(50) = 14 nM. AP23464 ab... |
|
T18693 |
SNIPER(ABL)-049
|
|
Others
|
|
SNIPER(ABL)-049, a compound that conjugates Imatinib (ABL inhibitor) with Bestatin (IAP ligand) through a linker, effectively reduces BCR-ABL protein levels, demonstrating a DC50 of 100 μM[1]. |
|
T18695 |
SNIPER(ABL)-058
|
|
Others
|
|
SNIPER(ABL)-058, a compound that links Imatinib (ABL inhibitor) with a derivative of LCL161 (IAP ligand) through a linker, effectively decreases BCR-ABL protein levels, achieving a half-maximal degradation concentration ... |
|
T61731 |
PPARγ agonist 4
|
|
|
|
PPARγ agonist 4 (Compound 18b), a potent and selective PPARγ agonist, demonstrates antitumor efficacy only when used in conjunction with Imatinib. Notably, PPARγ agonist 4 does not exhibit cytotoxic effects on either non... |
|
T69296 |
PHA-680626
|
|
|
|
PHA-680626 is a potent and selective PLK inhibitor. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of bot... |
|
T63450 |
BCR-ABL-IN-6
|
|
|
|
BCR-ABL-IN-6 (9h) is an imatinib derivative and a selective inhibitor of Bcr-Abl kinase that acts on Bcr-AblWT (IC50: 4.6 nM) and Bcr-AblT3151 (IC50: 277 nM). BCR-ABL-IN-6 (9h) was able to be used in the study of chronic... |
|
T71654 |
APcK110
|
|
|
|
APcK110 is a novel Kit inhibitor . APcK110 inhibits proliferation of the mastocytosis cell line HMC1.2 and the SCF-responsive cell line OCI/AML3 in a dose-dependent manner . APcK110 is a more potent inhibitor of OCI/AML3... |
|
T79711 |
Antitumor photosensitizer-4
|
|
Apoptosis
|
|
Antitumor Photosensitizer-4 (compound 10b), a conjugate of dasatinib and imatinib, serves as a potent tyrosine kinase inhibitor (TKI) targeting ABCG2. This photosensitizer (PS) induces apoptosis and reactive oxygen speci... |
